NEA Parnter Sara Nayeem will speak on a panel at the Orphan Drugs and Rare Diseases Conference on Tuesday, June 28, 2016 at Westin Copely Place Boston in Boston, MA. Dr. Nayeem will participate in the panel entitled, Funding Early Opportunities in Orphan and Rare Disease Space: What To Look Out For?
Gaithersburg-based Emergent BioSolutions will manufacture one of the first potential vaccines to fight the Zika virus, it announced Monday.
Under a federal contract, Emergent (NYSE: EBS) will develop and manufacture the vaccine for the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. Emergent will develop the vaccine material from a base created by an undisclosed private company, university or institution and provided by BARDA, officials said.
Awards season in the Baltimore tech scene moved into summer mode at the American Visionary Art Museum last week, where the Maryland Incubator Company of the Year Awards were handed out.
Baltimore incubators were well represented, with companies from the Emerging Technology Centers, Betamore and Johns Hopkins FastForward picking up honors.
John F. Kennedy introduced himself to the American electorate through his book Profiles in Courage presenting stories of public officials daring to confront ill conceived movements that sweep the country from time to time. They did so while being vilified by the press and many had their careers destroyed. While history shows they were correct, that was little solace at the time. Here’s how the publisher summarized Kennedy’s theme: “Courage, the courage to do what a person rightfully should do, despite the personal consequences, was a trait of character shared by them all.”
As carpenters finished an elegantly crafted deck near Greenmount Avenue and Oliver Street, I had a thought:
Where is the “gritty Greenmount” described in news articles a few years ago?
Montgomery County is participating in an important regional initiative called the Global Cities Initiative aimed at helping our businesses export and connecting our local economy with the global market.
Nationally, this initiative is led by JP Morgan and the Brookings Institution. In the National Capital Region, it is a collaborative effort between the Greater Washington Board of Trade, the Metropolitan Washington Council of Governments, and the Consortium of Universities of the Washington Metropolitan Area and numerous other regional partners.
The Brexit votes have been counted. The Brits have decided to leave the European Union. And the financial markets are taking it hard. Right now, futures on the London stock exchange are down 8%. The pound is down 9.8 percent, more than double its previous record decline of 4.1 percent. We’re living in interesting times.
Throughout the United States, innovation districts have been proposed with varying degrees of emphasis on inclusivity and opportunity. In January 2016, a public-private partnership representing many of Baltimore’s most influential anchor institutions, community-based organizations, and private companies declared their intent to develop an innovation district in West Baltimore dubbed the “Innovation Village.” This week, the Innovation Village steering committee announced several initiatives aimed at supporting inclusive economic growth in West Baltimore neighborhoods including free Wi-Fi, entrepreneurial assistance programs, and the development of a food hub.
Thousand Oaks-based biotech giant Amgen has put its backing behind a new, life sciences incubator, called QB3@953. According to Amgen, it will provide a five year, platinum sponsorship of the San Francisco life sciences incubator, to accelerate the development of new therapies to improve human health. Financial details of the sponsorship were not detailed. As part of that sponsorship, Amgen said it will be providing two awards each year with a company receiving one year of lab space at QB3@953, in addition to connections to Amgen’s executives and other resources. QB3@953 provides lab space to life sciences startups, which Amgen says is a “key obstacle” for life sciences startups. A similar effort, the Ventura BioCenter, operates just around the corner from Amgen in the Thousand Oaks area.
What is success? Is it the amount of money you have in your bank account, at any given point? Is it that feeling you get after delivering a killer presentation, or even a pretty decent bar joke? Or is it something bigger—something wholly unnamable, undefinable, immeasurable, and totally subjective?
